



Product Description

Phoenix Relax is designed for use anytime, creating the general sense of wellbeing and relaxation with a mid-level of sedation. Containing specific ratios of cannabinoids and terpenes known to maximize the relaxation effects without creating too much sedation or inducing sleep. Additional dosing may be used

Cannabinoid Extract Proprietor Compound

CANNABIDIOL (CBD), CANNABIGEROL (CBG), >0.3% TETRAHYDRACANNABINOL (THC) AND OTHER TRACE CANNABINOIDS
A-HUMULENE , B-CARYOPHYLLENE , B-MYRCENE, LINALOOL , P-CYMENE, A-PINENE, B-PINENE

Other Ingredients

Medium-chain triglycerides (MCT) derived from coconut, Water, Glycerin, Cannabis Extracts, Kolliphor HS-15, Peppermint Oil.

Global Distribution Strategy

Phoenix Relax is defined under most cannabis laws with respect to sales and distribution, as an extract from Industrial Hemp. The use of these specific strains allow the product to be sold under an ever expanding global acceptance of CBD and its safety and low risk of addiction as cited by the World Health Organization. This allows for a greater level of distribution due the reduced levels of product control requirements.

<p align="center">Online</p> <p>Due the product being classified as "CBD from Industrial Hemp", this product can be sold Online and exported to over 20 countries. To facilitate this, the product will be made available as Phoenix Relax (LE), without specific medical claims within the jurisdictions offered, unless otherwise approved.</p>	<p align="center"> Australia</p> <p>Partner with local licensed producer for distribution under medical cannabis laws. Local clinical trials to be completed in 2024.</p>	<p align="center"> Europe</p> <p>Online distribution under generic CBD classification. NHMA partnerships 2022 and clinical trials to be commenced in 2024.</p>
<p align="center">Global Distribution</p> <p>Now that 47 countries have legalized medical cannabis, the inter-country trade is starting to expand. Phoenix Life is focused on import and export of its products from company owned and partnered production facilities. Phoenix Relax will initially be sold Online & in National Healthcare Management Agreements.</p>	<p align="center"> United States</p> <p>Online distribution under hemp CBD classification. Equality License partnership. Clinical trials to be commenced late 2024.</p>	<p align="center"> Vanuatu</p> <p>Initial products to be supplied by the USA. Roll-out as part of distribution under approved NHMA.</p>

Medical History and Development Information

Initial and ongoing studies show that the introduction of the specific dose of CBD with the included terpene profile significantly reduced levels of anxiety and created a general sense of wellbeing. Designed to provide a natural relaxation without sedation. The product is designed to be sold in Soft Gel Capsules and Sub-lingual Sprays.

Clinical Stage

INITIAL CANDIDATE STRAIN / FORMULATION SELECTED
EFFICACY DATA COLLABORATED WITH RESEARCH TEAM
INITIAL PATIENT GROUP SUCCESS
LARGER PATIENT GROUP SUCCESS
FORMALIZED CLINICAL TRIALS
APPROVED FOR SALE IN LOCAL MARKET
EXEMPTION AVAILABLE FOR IMMEDIATE SALES

LEGEND Completed Next Step Not Completed

Medical Evidence, Citations and other References

US National Library of Medicine - a part of the National Institutes of Health details the following study and abstract More details are available at <https://pubmed.ncbi.nlm.nih.gov/24923339/>
 2014;13(6):953-60. DOI: 10.2174/1871527313666140612114838 PMID: 24923339

Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa

Author(s): Alexandre R de Mello Schier, Natalia P de Oliveira Ribeiro, Danielle S Coutinho, Sergio Machado, Oscar Arias-Carriv2n, Jose A Crippa, Antonio W Zuardi, Antonio E Nardi, Adriana C Silva
 Abstract: Anxiety and depression are pathologies that affect human beings in many aspects of life, including social life, productivity and health. Cannabidiol (CBD) is a constituent non-psychotomimetic of Cannabis sativa with great psychiatric potential, including uses as an antidepressant-like and anxiolytic-like compound. The aim of this study is to review studies of animal models using CBD as an anxiolytic-like and antidepressant-like compound. Studies involving animal models, performing a variety of experiments on the above-mentioned disorders, such as the forced swimming test (FST), elevated plus maze (EPM) and Vogel conflict test (VCT), suggest that CBD exhibited an anti-anxiety and antidepressant effects in animal models discussed. Experiments with CBD demonstrated non-activation of neuroreceptors CB1 and CB2. Most of the studies demonstrated a good interaction between CBD and the 5-HT1A neuro-receptor.